Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer

2016633 citationsJournal Articlebronze Open Access

Authors

Howard I. Scher · Memorial Sloan Kettering Cancer Center

David Lu · Epic Sciences (United States)

Nicole A. Schreiber · Memorial Sloan Kettering Cancer Center

Jessica Louw · Epic Sciences (United States)

Ryon P. Graf · Epic Sciences (United States)

Hebert Alberto Vargas · Memorial Sloan Kettering Cancer Center

Ann Johnson

Abstract

The results validate CTC nuclear expression of AR-V7 protein in men with mCRPC as a treatment-specific biomarker that is associated with superior survival on taxane therapy over ARS-directed therapy in a clinical practice setting. Continued examination of this biomarker in prospective studies will further aid clinical utility.

Topics & Keywords

Prostate Cancer Treatment and Research Cancer Cells and Metastasis Cancer Genomics and Diagnostics

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JAMA Oncology

Volume 2, Issue 11, pp. 1441-1441

DOI: 10.1001/jamaoncol.2016.1828

Field-Weighted Citation Impact: 83.19